Tag: Japan

Eisai Agreed to Transfer Rights for Tazemetostat to Royalty Pharma

Eisai Co., Ltd. announced that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic...

Rentschler Biopharma to Develop Existing Collaboration with Summit Pharmaceuticals in Japan

Rentschler Biopharma SE will further develop the existing collaboration in Japan with Summit Pharmaceuticals International Corporation (SPI), a wholly owned subsidiary of Sumitomo Corporation. Thro...

Trintellix® for Depression Treatment Approved in Japan

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S jointly announced that the MHLW of Japan approved Trintellix® (vortioxetine) for the treatment of depression and depressed state. Vortioxetine...

Daiichi Sankyo Launched Oxycodone Extended Release Tablets NX “Daiichi Sankyo” in Japan

Daiichi Sankyo Company Limited announced it has launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets for sustained cancer pain treatment in Japan: Oxycodone E...

GSK Submitted Application for Daprodustat in Japan

gsk
GlaxoSmithKline announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare seeking marketing approval for daprodustat, an oral hypoxia-inducible f...

Sysmex Obtained Japanese Approval for OncoBEAM™ RAS CRC Kit

Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM™ RAS CRC Kit, used for blood-based circulating tumor DNA molecular testing of mutations in the RAS gene f...

Astellas Pharma Submitted Application for XTANDI® in Japan

Astellas Pharma Inc. announced that it has submitted a supplemental new drug application for the oral androgen receptor signaling inhibitor XTANDI® (generic name: enzalutamide) to add the indication f...

MediciNova Announced Collaboration with the Japanese Research Center

research
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that it will initiate a comprehensive research collaborati...

ONPATTRO for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Approved in Japan

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ONPATTRO®(patisiran) for the treatment of h...

AstraZeneca’s Breztri Aerosphere Approved in Japan

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy to relieve symptoms of chronic...

Roche’s Personalised Medicine Rozlytrek Approved in Japan

roche
Roche announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients with neurotrophic tyrosine receptor ...

Takeda’s Entyvio® Received Approval in Japan

drugsapproved
Takeda Pharmaceutical Company Limited announced that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for an additional indication for Entyvio® (generic name: vedolizuma...

Forxiga Got Another Approval

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). Elisabeth Björk, Senio...

GARDP, Eisai and Takeda join Forces to search new Antibiotics

Under a new agreement the Japanese pharma companies will access and screen molecules from Eisai and Takeda’s chemical libraries. Both libraries will be tested by the Institut Pasteur Korea, in order t...

Sun Pharma to acquire Japanese drug manufacturer

sun pharma
Sun Pharma announced it has entered into a agreement to acquire Pola Pharma, a company engaged in research and development, manufacture, sale and distribution of branded and generic products.

Alvotech and Fuji Pharma signed an exclusive partnership agreement

clinical-trials
Alvotech (Iceland) and Fuji Pharma (Japan) announced that the two companies are entering into an exclusive partnership.